" FSH-blocking Antibody Could Treat Obesity, Osteoporosis" - Phil Neuffer
In this video exclusive, Mone Zaidi, MD, PhD, professor of medicine at the Icahn School of Medicine at Mount Sinai and director of the Mount Sinai Bone Program, discusses his two decades of research on the role of pituitary hormones in the regulation of the skeleton, particularly in postmenopausal women. Dr. Zaidi’s work has revealed that there may be more direct action by some hormones on bone loss in osteoporosis. Specifically, he said rising follicle-stimulating hormone (FSH) levels in the face of normal estrogen levels can lead to high rates of bone loss. Preliminary studies in mice suggest that certain antibodies against FSH can minimize bone loss. Dr. Zaidi said this antibody can also contribute to body fat loss, with white fat being converted into more energy critical fat tissue. Due to this potential action, according to Dr. Zaidi, this could prove to be an effective treatment for obesity and osteoporosis in humans.
— Mone Zaidi, MD, PhD, Professor, Medicine, Endocrinology, Diabetes and Bone Disease, Pharmacological Sciences, Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, Director, Mount Sinai Bone Program
